<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8434" href="/d/html/8434.html" rel="external">see "Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information"</a> and <a class="drug drug_patient" data-topicid="11470" href="/d/html/11470.html" rel="external">see "Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F10514505"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thromboembolic events have been reported during postmarketing surveillance following infusion of anti-inhibitor coagulant complex, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135834"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Feiba</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53377860"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Feiba NF</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2528322"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F135846"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Anti-inhibitor coagulant complex (Human) contains mainly nonactivated therapeutic levels of factors II, IX, and X and mainly activated factor VII. Dosage is expressed in units of factor VIII inhibitor bypassing activity and is dependent upon the severity and location of bleeding. Maximum dose should only be exceeded if bleeding severity warrants; monitor closely for disseminated intravascular coagulation, coronary ischemia and/or signs and symptoms of other thromboembolic events.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2bc41a20-cec7-4468-9679-8405c0015eeb">Control and prevention of bleeding episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Control and prevention of bleeding episodes:</b> Infants, Children, and Adolescents: <b>Note:</b> Dosage will vary with the bleeding site and severity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Joint hemorrhage:</i> IV: 50 to 100 units/kg/dose every 12 hours until pain and acute disabilities are improved; maximum daily dose: 200 units/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mucous membrane bleeding:</i> IV: 50 to 100 units/kg/dose every 6 hours for at least one day or until bleeding is resolved; maximum daily dose: 200 units/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Soft tissue hemorrhage (eg, retroperitoneal bleeding):</i> IV: 100 units/kg/dose every 12 hours until resolution of bleed; maximum daily dose: 200 units/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other severe hemorrhages (eg, CNS bleeds):</i> IV: 100 units/kg/dose every 6 to 12 hours until resolution of bleed; maximum daily dose: 200 units/kg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="468181fc-f980-4f18-bdbd-904170da2420">Perioperative management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perioperative management:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preoperative:</i> IV: 50 to 100 units/kg (single dose) administered immediately prior to surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postoperative:</i> IV: 50 to 100 units/kg/dose every 6 to 12 hours until resolution of bleed and healing is achieved; maximum daily dose: 200 units/kg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dee5e49b-66f6-4ffc-a18b-662c7655063c">Routine prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Routine prophylaxis:</b> Infants, Children, and Adolescents: IV: 85 units/kg/dose every other day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065127"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51065128"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F135836"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8434" href="/d/html/8434.html" rel="external">see "Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Anti-inhibitor coagulant complex (human) contains mainly nonactivated therapeutic levels of factors II, IX, and X and mainly <b>
<i>activated</i></b> factor VII<b>. </b>Dosage is expressed in units of factor VIII inhibitor bypassing activity.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f674c156-bc2b-48d9-9244-0b8b02c7b5f2">Control and prevention of bleeding episodes in patients with hemophilia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Control and prevention of bleeding episodes in patients with hemophilia:</b> IV: <b>Note:</b> Considered a first-line treatment when factor VIII inhibitor titer is &gt;5 Bethesda units (BU) (antihemophilic factor VIII concentrate may be preferred when titer &lt;5 BU). Avoid use in patients with hemophilia A with inhibitors receiving concomitant emicizumab prophylaxis due to increased risk of thrombotic microangiopathy and for patients with hemophilia B with inhibitors due to risk for allergic reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing guidelines:</b> 50 to 100 units/kg/dose. Dosage, dosing frequency, and duration of treatment depend on the location and extent of bleeding and clinical condition of the patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Joint hemorrhage:</i> 50 to 100 units/kg every 12 hours until pain and acute disabilities are improved (maximum: 100 units/kg/dose; 200 units/kg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mucous membrane bleeding:</i> 50 to 100 units/kg every 6 hours for at least 1 day or until bleeding is resolved (maximum: 100 units/kg/dose; 200 units/kg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Soft tissue hemorrhage (eg, retroperitoneal bleed):</i> 100 units/kg every 12 hours until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Other severe hemorrhage (eg, intracranial hemorrhage):</i> 100 units/kg every 6 to 12 hours; continue until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Preoperative: 50 to 100 units/kg (single dose) administered immediately prior to surgery.</p>
<p style="text-indent:-2em;margin-left:8em;">Postoperative: 50 to 100 units/kg every 6 to 12 hours until resolution of bleed and healing is achieved (maximum: 100 units/kg/dose; 200 units/kg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Routine prophylaxis:</i> 85 units/kg every other day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0536f641-21ee-4ebf-ae6b-0b41d8311f0c">Hemorrhage due to acquired hemophilia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhage (moderate to severe) due to acquired hemophilia (off-label use):</b> IV: <b>Optimal dosing has not been established:</b> 50 to 100 units/kg every 8 to 12 hours until bleeding controlled has been suggested; may continue for 24 to 72 hours based on site, type, and severity of bleeding (maximum: 200 units/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19336751','lexi-content-ref-14962206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19336751','lexi-content-ref-14962206'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78b272a3-5cf0-402d-b52a-5ef8cab94be4">Intracranial hemorrhage, pentasaccharide-mediated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial hemorrhage, </b>
<b>pentasaccharide-mediated (eg, fondaparinux) (full-therapeutic dose)</b>
<b> (off-label use):</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">20 units/kg. <b>Note:</b> In patients receiving fondaparinux for venous thromboembolism prophylaxis (ie, not a full therapeutic dose), the Neurocritical Care Society and Society of Critical Care Medicine guidelines suggest <i>against</i> reversal unless there is evidence of bioaccumulation or impaired clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="024f78ef-06f2-4fbe-9f34-eef88844d6da">Life-threatening bleeding associated with non-vitamin K antagonists</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Life-threatening bleeding associated with non-vitamin K antagonists (off-label use):</b>
<b>Note:</b> Generally used for life-threatening bleeding or bleeding into a critical organ that is not controlled with maximal supportive measures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31732375','lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31732375','lexi-content-ref-30916798'])">Ref</a></span>). The use of anti-inhibitor coagulant complex may be associated with a higher risk of thrombosis compared to nonactivated prothrombin complex concentrate, especially with higher doses; monitor closely for arterial and venous thrombosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral direct factor Xa inhibitor-mediated (apixaban, betrixaban, edoxaban, rivaroxaban [if andexanet alfa unavailable]): IV: 50 units/kg once, in addition to other supportive measures as clinically indicated (eg, activated charcoal [if ingestion is within 2 to 4 hours], antifibrinolytic agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-26714677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Direct thrombin inhibitor-mediated (argatroban, dabigatran, bivalirudin, desirudin [if idarucizumab unavailable]): IV: 50 units/kg once, in addition to other supportive measures as clinically indicated (eg, activated charcoal [if ingestion is within 2 to 4 hours], hemodialysis, antifibrinolytic agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-30916798','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-30916798','lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76cff3f9-d082-4ba6-849a-cca520f8d9fc">Reversal of dabigatran in patients who require urgent procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of dabigatran in patients who require urgent procedure (if idarucizumab unavailable) (off-label use): Note:</b> Reversal agent should be administered only if the procedure cannot safely be performed while the patient is anticoagulated or cannot be delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30916798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 50 units/kg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30916798'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991319"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988662"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F135816"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hemarthrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain, thromboembolic complications (including cerebrovascular accident, deep vein thrombosis, pulmonary embolism)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, drowsiness, hypoesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Feeling hot, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, wheezing</p></div>
<div class="block coi drugH1Div" id="F135828"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known anaphylactic or severe hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation, including factors of the kinin generating system; disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction)</p></div>
<div class="block war drugH1Div" id="F135813"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity and allergic reactions (including severe and systemic reactions [eg, anaphylaxis with urticaria and angioedema, bronchospasm, circulatory shock]) have been observed following administration. Discontinue immediately with signs/symptoms of severe hypersensitivity reactions and provide appropriate supportive care.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion reactions (eg, chills, pyrexia, hypertension) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b>[US Boxed Warning]: Thromboembolic events (including venous thrombosis, pulmonary embolism, MI, and stroke) have been reported following administration of anti-inhibitor coagulant complex, particularly with administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events,</b> especially if more than 200 units/kg/day is administered. Use with caution in patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with factor VIIa. Weigh the potential benefit of treatment against the potential risk of these thromboembolic events. Monitor patients receiving &gt;100 units/kg for the development of DIC, acute coronary ischemia, and signs/symptoms of other thromboembolic events. If clinical signs/symptoms occur, discontinue use. In an emicizumab clinical trial where patients were also administered anti-inhibitor coagulant complex for breakthrough bleeding, there were reported cases of thrombotic microangiopathy (TMA). TMA has not been reported in clinical studies of anti-inhibitor coagulant complex. Use with caution and monitor closely if anti-inhibitor coagulant complex is used in patients receiving emicizumab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Factor VIII: Product contains minute amounts of factor VIII which may cause an anamnestic response; anamnestic rises were not associated with reduced efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents that could transmit disease. During the manufacturing process, screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer and/or to FDA MedWatch. Patients with signs/symptoms of infection (eg, fever, chills, drowsiness) should be encouraged to consult health care provider.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX. Use of antifibrinolytics within ~6 to 12 hours after the administration of anti-inhibitor coagulant complex is not recommended.</p></div>
<div class="block dosfc drugH1Div" id="F25573580"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">FEIBA strengths expressed in terms of Factor VIII inhibitor bypassing activity with nominal strength values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F135824"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Feiba: 500 units (1 ea); 1000 units (1 ea); 2500 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F135810"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53079516"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Feiba Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $3.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $3.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2500 unit (Price provided is per AHF Unit): $3.14</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53377861"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Feiba NF: 1000 units (1 ea); 2500 units (1 ea)</p></div>
<div class="block adip drugH1Div" id="F53565355"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">One unit of activity is defined as that amount of anti-inhibitor coagulant complex that shortens the activated partial thromboplastin time (aPTT) of a high titer factor VIII inhibitor reference plasma to 50% of the blank value.</p></div>
<div class="block admp drugH1Div" id="F52612247"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV injection or infusion only. Flush line with NS prior to and following administration; do not administer in the same tubing or container with other medications. Use plastic luer lock syringes; anti-inhibitor coagulant complex may stick to the surface of all-glass syringes. Maximum infusion rate: 2 units/kg/minute. A syringe pump may be used to control the rate of administration. Complete infusion within 3 hours of reconstitution.</p></div>
<div class="block adm drugH1Div" id="F135826"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV injection or infusion only; maximum infusion rate: 10 units/kg/minute. A syringe pump may be used to control the rate of administration. Use plastic luer lock syringes (anti-inhibitor coagulant complex may stick to the surface of all-glass syringes); do not administer in the same tubing or container with other medications. Following reconstitution, administer immediately and complete infusion within 3 hours.</p></div>
<div class="block sts drugH1Div" id="F135831"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 25°C (36°F to 77°F); store in the original package to protect from light. Do <b>not</b> freeze. Following reconstitution, do not refrigerate and administer immediately, completing administration within 3 hours.</p></div>
<div class="block usep drugH1Div" id="F53565472"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Control and prevention of bleeding episodes, perioperative bleeding management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B with inhibitors (All indications: FDA approved in ages &gt;28 days and adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Not indicated for the treatment of bleeding resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX.</p></div>
<div class="block cyt drugH1Div" id="F13298760"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2869874"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Concizumab: Anti-inhibitor Coagulant Complex (Human) may enhance the thrombogenic effect of Concizumab.  Management: Discontinue anti-inhibitor coagulant complex (aPCC) at least 48 hours before starting concizumab. If aPCC is required during concizumab prophylaxis, use the lowest possible effective aPCC dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Emicizumab: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor VIIa (Recombinant): Anti-inhibitor Coagulant Complex (Human) may enhance the thrombogenic effect of Factor VIIa (Recombinant).  Management: Consider avoiding concomitant use of factor VIIa (recombinant) and activated prothrombin concentrates, such as anti-inhibitor coagulant complex (human), due to an increased risk of developing thrombotic events.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F2869876"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F2869871"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Limited outcome information is available from a pregnancy registry following use of anti-inhibitor coagulant complex (human) in pregnant patients with acquired hemophilia A (Tengborn 2012). Other products are preferred for the routine prophylaxis of bleeding events in pregnant patients with known hemophilia (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]). However, the use of anti-inhibitor coagulant complex (human) may be considered in select patients with bleeding associated with postpartum acquired hemophilia A (a recombinant product may be preferred) (Huth-Kuhne 2009; Kruse-Jarres 2017; Windyga 2019).</p></div>
<div class="block mopp drugH1Div" id="F53565447"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for control of bleeding; signs and symptoms of disseminated intravascular coagulation (DIC) (blood pressure changes, pulse rate changes, chest pain/cough, fibrinogen, platelet count, fibrin-fibrinogen degradation products, significantly-prolonged thrombin time, PT, or partial thromboplastin time), acute coronary ischemia and other thromboembolic events, especially if &gt;100 units/kg is administered; hemoglobin and hematocrit; hypotension; signs and symptoms of hypersensitivity reactions (including anaphylaxis). <b>Note:</b> Tests used to monitor hemostatic efficacy, such as aPTT and thromboelastography, are <b>not</b> useful for monitoring responses with anti-inhibitor coagulant complex (Hoffman 2012). Dosing to normalize these values may result in DIC.</p></div>
<div class="block pha drugH1Div" id="F23682864"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Multiple interactions of the components in anti-inhibitor coagulant complex restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor.</p></div>
<div class="block phk drugH1Div" id="F20453114"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Peak thrombin generation: Within 15 to 30 minutes (Varadi 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 8 to 12 hours (based on thrombin generation) (Varadi 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 4 to 7 hours (based on thrombin generation) (Varadi 2003)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13276659"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Feiba tim 4</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Feiba s tim 4</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf | Feiba tim</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf | Feiba tim</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Feiba tim 4</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Feiba | Feiba tim 4</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf | Feiba tim 4</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Feiba tim 3</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Feiba | Feiba nippon zoki</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Feiba tim</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Feiba | Feiba tim</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Feiba tim | Feiba Tim 4 Immuno</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Feiba | Feiba Immuno Tim 4</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Feiba Tim 4 Immuno</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf | Feiba tim 4</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Feiba | Feiba nf</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Feiba nf</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Feiba tim 4</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Feiba Tim 4 Immuno</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Feiba</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31732375">
<a name="31732375"></a>Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. <i>Ann Emerg Med</i>. 2019;S0196-0644(19)31181-31183. doi:10.1016/j.annemergmed.2019.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/31732375/pubmed" id="31732375" target="_blank">31732375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30916798">
<a name="30916798"></a>Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. <i>Am J Hematol</i>. 2019;94(6):697-709. doi:10.1002/ajh.25475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/30916798/pubmed" id="30916798" target="_blank">30916798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23474679">
<a name="23474679"></a>Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. <i>Crit Care Med</i>, 2013;41(5):e42-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/23474679/pubmed" id="23474679" target="_blank">23474679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24244342">
<a name="24244342"></a>Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. <i>PLoS One</i>. 2013;8(11):e78696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/24244342/pubmed" id="24244342" target="_blank">24244342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.DOO">
<a name="expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24508114">
<a name="24508114"></a>Faust AC, Peterson EJ. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report. <i>J Emerg Med</i>. 2014;46(4):525-529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/24508114 /pubmed" id="24508114 " target="_blank">24508114 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FEIBA.1">
<a name="FEIBA.1"></a>FEIBA (anti-inhibitor coagulant complex) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FEIBA.2">
<a name="FEIBA.2"></a>FEIBA NF (anti-inhibitor coagulant complex) [prescribing information]. Toronto, Ontario, Canada: Shire Pharma Canada ULC; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016; 24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22186946">
<a name="22186946"></a>Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. <i>Thromb Haemost</i>. 2012;107(2):253-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/22186946/pubmed" id="22186946" target="_blank">22186946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25179520">
<a name="25179520"></a>Halim AB, Samama MM, Mendell J. Ex vivo reversal of the anticoagulant effects of edoxaban. <i>Thromb Res</i>. 2014;134(4):909-913.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/25179520/pubmed" id="25179520" target="_blank">25179520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324838">
<a name="26324838"></a>Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/26324838/pubmed" id="26324838" target="_blank">26324838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26022637">
<a name="26022637"></a>Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/26022637/pubmed" id="26022637" target="_blank">26022637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22632160">
<a name="22632160"></a>Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. <i>J Thromb Haemost</i>. 2012;10(8):1478-1485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/22632160/pubmed" id="22632160" target="_blank">22632160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19336751">
<a name="19336751"></a>Huth-Kuhne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. <i>Haematologica. </i>2009;94(4):566-575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/19336751/pubmed" id="19336751" target="_blank">19336751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23584314">
<a name="23584314"></a>Kiraly A, Lyden A, Periyanayagam U, et al, Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: case report from the northwestern emergency medicine residency. <i>Am J Ther</i>. 2013;20(3):300-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/23584314/pubmed" id="23584314" target="_blank">23584314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28470674">
<a name="28470674"></a>Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. <i>Am J Hematol</i>. 2017;92(7):695-705. doi:10.1002/ajh.24777<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/28470674/pubmed" id="28470674" target="_blank">28470674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12828680">
<a name="12828680"></a>Lloyd Jones M, Wight J, Paisley S, et al. Control of bleeding in patients with Haemophilia A with inhibitors: a systematic review.<i>Haemophilia</i>, 2003, 9(4):464-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/12828680/pubmed" id="12828680" target="_blank">12828680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17124095">
<a name="17124095"></a>Ma AD and Carrizosa D, “Acquired Factor VIII Inhibitors: Pathophysiology and Treatment,” <i>Hematology Am Soc Hematol Educ Program</i>, 2006: 432-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/17124095/pubmed" id="17124095" target="_blank">17124095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22627883">
<a name="22627883"></a>Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers [published correction appears in <i>Thromb Haemost</i>. 2013;109(1):169]. <i>Thromb Haemost.</i> 2012;108(2):217-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/22627883/pubmed" id="22627883" target="_blank">22627883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24296541">
<a name="24296541"></a>Maurice-Szamburski A, Graillon T, Bruder N. Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban. <i>J Neurosurg Anesthesiol</i>. 2014 Apr;26(2):183. doi:10.1097/ANA.0000000000000030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/24296541/pubmed" id="24296541" target="_blank">24296541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15558804">
<a name="15558804"></a>Monahan PE and Aledort LM, “Factors Affecting Choice of Hemostatic Agent for the Hemophilia Patient With an Inhibitor Antibody,” <i>Am J Hematol</i>, 2004, 77(4):346-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/15558804/pubmed" id="15558804" target="_blank">15558804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.2017">
<a name="NHF.2017"></a>National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Guidelines-for-Perinatal-Management-of-Women-with-Bleeding-Disorders-and-Carriers-of-Hemophilia-A-and-B. Published September 17, 2017. Accessed December 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23666496">
<a name="23666496"></a>Neyens R, Bohm N, Cearley M, et al. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG) to guide decision-making. <i>J Thromb Thrombolysis</i>. 2014;37(2):80-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/23666496 /pubmed" id="23666496 " target="_blank">23666496 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al on behalf of the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy. Green-top guideline No. 71. <i>BJOG</i>. 2017;124:e193–e263. doi:10.1111/1471-0528.14592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24529498">
<a name="24529498"></a>Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. <i>Thromb Res</i>. 2014;133(4):671-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/24529498/pubmed" id="24529498" target="_blank">24529498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14962206">
<a name="14962206"></a>Sallah S, “Treatment of Acquired Haemophilia With Factor Eight Inhibitor Bypassing Activity,” <i>Haemophilia</i>, 2004, 10(2):169-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/14962206/pubmed" id="14962206" target="_blank">14962206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24383848">
<a name="24383848"></a>Schulman S, Ritchie B, Goy JK, Nahirniak S, Almutawa M, Ghanny S. Activated prothrombin complex concentrate for dabigatran-associated bleeding. <i>Br J Haematol</i>. 2014;164(2):308-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/24383848 /pubmed" id="24383848 " target="_blank">24383848 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22901076">
<a name="22901076"></a>Tengborn L, Baudo F, Huth-Kuhne A, et al. EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. <i>BJOG</i>. 2012;119(12): 1529–1537. doi:10.1111/j.1471 0528.2012.03469.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/22901076/pubmed" id="22901076" target="_blank">22901076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15385045">
<a name="15385045"></a>Tjonnfjord GE, “Activated Prothrombin Complex Concentrate (FEIBA®) Treatment During Surgery in Patients with Inhibitors to Factor VIII/IX: The Updated Norwegian Experience, <i>Haemophilia</i>, 2004, 10(Supp 2):41-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/15385045/pubmed" id="15385045" target="_blank">15385045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14629472">
<a name="14629472"></a>Varadi K, Negrier C, Berntorp E, et al, “Monitoring the Bioavailability of FEIBA With a Thrombin Generation Assay,” <i>J Thromb Haemost</i>, 2003, 1(11):2374-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/14629472/pubmed" id="14629472" target="_blank">14629472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147769">
<a name="23147769"></a>Weitz JI, Quinlan DJ, and Eikelboom JW, “Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran,” <i>Circulation</i>, 2012, 126(20):2428-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/23147769/pubmed" id="23147769" target="_blank">23147769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31276188">
<a name="31276188"></a>Windyga J, Baran B, Odnoczko E, et al. Treatment guidelines for acquired hemophilia A. <i>Ginekol</i>
<i>Pol</i>. 2019;90(6):353-364. doi:10.5603/GP.2019.0063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/31276188/pubmed" id="31276188" target="_blank">31276188</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12912 Version 145.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
